All News about Ionis Pharmaceuticals
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Recap: Ionis Pharmaceuticals Q1 Earnings
May 03, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Ionis Pharmaceuticals's Earnings Outlook
May 02, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/04/26/biib.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/04/25/analysis-gc071ae9e3_1920.jpg?width=1200&height=800&fit=crop)
![](/next-assets/images/schema-image-default.png)
Analyst Expectations for Ionis Pharmaceuticals's Future
April 11, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Analyst Ratings for Ionis Pharmaceuticals
March 21, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/ep_us_feature_image_1441.jpeg?width=1200&height=800&fit=crop)
Ionis Pharmaceuticals's Earnings Outlook
February 21, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_2079.png?width=1200&height=800&fit=crop)
Analyst Expectations for Ionis Pharmaceuticals's Future
January 19, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/04/25/biib.png?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2022/02/cancer.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/04/24/aapharma_3.png?width=1200&height=800&fit=crop)
![](https://g.foolcdn.com/editorial/images/728370/a-doctor-and-patient-at-an-appointment.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/04/12/arwr.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/03/27/azn-ions.png?width=1200&height=800&fit=crop)
The Latest Analyst Ratings for Ionis Pharmaceuticals
December 21, 2022
Via Benzinga
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed
December 13, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_7313.png?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2019/05/Stock-IonisHQ-01-company.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/03/23/biib.png?width=1200&height=800&fit=crop)
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/03/16/biib.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/02/21/ions_logo_light__a1a3db690556ba7e6b07c28b193b235b.png?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2018/12/Stock-DrugDesigner-01-adobe.jpg)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_9525.png?width=1200&height=800&fit=crop)
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
December 21, 2022
Via Benzinga
![](https://www.investors.com/wp-content/uploads/2022/11/Stock-neurologybrain-02-adobe.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/11/10/image-phillips_66.png?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/11/04/ions_logo_light__a1a3db690556ba7e6b07c28b193b235b.png?width=1200&height=800&fit=crop)
Ionis Regains Rights To Thrombosis Candidate From Bayer
November 04, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.